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Abstract
Background
Hereditary Tyrosinemia Type 1 (TT1) is an autosomal recessive disorder that is caused
by the deficiency of the FAH enzyme, resulting in the elevation of tyrosine and its byproducts in
the blood. This buildup of toxic metabolites in a child’s bloodstream leads to catastrophic effects,
which will eventually lead to death if not treated. However, the only treatments available for
children with TT1 include pharmacological measures with Nitisinone (Orfadin) and a liver
transplant. Unfortunately, both treatments carry major health risks along with their benefits.
While liver transplants require life-long management and the risk of rejection, Nitisinone has
also been linked to dangerous side effects. Studies have shown that Nitisinone leads to severe
cognitive impairment while treating children with TT1, although the cause for the neurocognitive
impairments is still unknown. With evidence that the only pharmacologic treatment for TT1
causes impaired cognition in children, increased awareness and the development of improved
treatment is. This study will utilize the behavioral model, the Y-Maze, to test the effects of
Nitisinone on neurocognitive function, particularly memory and learning. The results did not
show differentiation among the carriers (FAH+/-) and the diseased (FAH-/-) mice.
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Introduction
Tyrosinemia type I (TT1) is an autosomal recessive disorder caused by the deficiency in
fumarylacetoacetate hydrolase (FAH) in the catabolic metabolism of tyrosine. This disorder
leads to elevated tyrosine and alpha-fetoprotein in the blood. If untreated, the buildup of tyrosine
and its byproducts, fumarylacetoacetate and succinylacetone, lead to serious medical problems,
including hepatic and renal disease. Tyrosinemia type I is treated with a low-tyrosine diet and
prescribed Nitisinone. Nitisinone inhibits 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme in
the tyrosine catabolic pathway, as shown in Figure 1. By inhibiting the normal catabolism of
tyrosine in patients with TT1, Nitisinone prevents the accumulation of catabolic intermediates,
which would otherwise be converted to the toxic metabolites that are responsible for the
observed liver and kidney toxicity seen in these patients. However, studies have shown that
Nitisinone may lead to severe neurological deficits. Unfortunately, there are no other
pharmacological treatments for children with TT1. The only other treatment option is a liver
transplant, which includes life-long management and a high risk for rejection.
This study will test the neurocognitive deficits associated with Nitisinone in order to
determine if these effects are caused by the prescribed medication or by the pathophysiology of
Tyrosinemia Type 1 itself. This study may also contribute to knowledge of the severity of the
neurocognitive effects of pharmacological treatment are for children with TT1 and if these
effects outweigh the therapeutic measures of the drug. With evidence that Nitisinone causes
impaired cognition, increased public awareness and the development of improved treatment is
necessary for children with Tyrosinemia Type 1.
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Review of Literature
The current pharmacological therapy for Tyrosinemia Type 1 (TT1) uses the drug 2-[2nitro-4-trifluoromethylbenzoyl]-1, 3-cyclohexanedione (NTBC), commonly referred to as
Nitisinone. Nitisinone prevents the toxic metabolic accumulations found in hereditary TT1 by
blocking 4-hydroxypheylpyruvate dioxygenase, an upstream enzyme, in the tyrosine degradation
pathway, as shown in Figure 1. Nitisinone effectively prevents the neurologic crisis, liver failure,
and hepatocellular carcinoma usually found with untreated hereditary TT1. However, as
Nitisinone biochemically switches the enzymatic defect found in TT1 to the defect found in
Tyrosinemia type III, tyrosine concentrations are ultimately increased, leading to impaired
cognitive function in patients taking the pharmacological therapy (Thimm et al., 2011). Higher
tyrosine levels found in Tyrosinemia type II and III are considered to be the main contributing
factor in the impaired cognitive functioning of these patients.
The neurocognitive impairment associated with Nitisinone treatment is still not proven to
be an effect of the pharmacological treatment rather than the disease pathophysiology itself. Mild
impaired cognitive function may have been an unobserved clinical manifestation of Tyrosinemia
Type I, a symptom that failed to be recognized before the use of Nitisinone because of the short
life span of untreated patients with Tyrosinemia Type I (Bendadi et al.,2013). Unfortunately,
there are few human or animal studies to support or refute this hypothesis. Bendadi et al. (2013)
and Laet et al. (2011) found a significant decrease in the Intelligence Quotient of a subset of
patients in whom IQ was regularly tested, as shown in Figure 2. However, similarly low IQs in
patients who had stopped taking Nitisinone after undergoing liver transplantation argues against
the acute toxicity of Nitisinone. Most likely, Nitisinone affects cognitive function indirectly, by
inducing profoundly elevated plasma tyrosine levels in patients. Inconclusive data could be
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attributed to the limited sample size or other issues with regard to tyrosine measurement in the
studies. The nature of the observed cognitive impairment remains unclear and the
pathophysiology causing the impairment is still not fully understood.
Furthermore, neurocognitive defects could be increased by the diet necessary for children
with TT1. Tyrosine levels can be reduced through a more restricted protein intake along with
Nitisinone therapy. Since phenylalanine and tyrosine compete for transport to the brain, the
combination for high tyrosine and low phenylalanine may lead to insufficient phenylalanine
transport to the brain, decreasing the amount of phenylalanine available for protein and
neurotransmitter synthesis. According to Bendadi et al. (2013) and Laet et al. (2011), this
shortage may cause a deviant cognitive development that can be expressed later in life with
mildly impaired cognitive function.

Low phenylalanine is known to be associated with a

decrease in IQ in patients with Phenylketonuria (PKU). Laet et al. (2011) observed patients with
the lowest IQ had mean phenylalanine concentrations below 40 umol/L during the first two years
of Nitisinone treatment.
Low phenylalanine levels in the brain also affect other amino acids in the brain. Neutral
amino acids cross the blood brain barrier with a common carrier thus any change in amino acid
concentrations will affect the uptake of other amino acid groups in the brain. Therefore, as
tyrosine levels rise, phenylalanine levels are lowered. Low phenylalanine levels affect serotonin
metabolism by causing an inhibition of tryptophan hydroxylase, the rate-limiting enzyme of
serotonin synthesis. Behavioral alterations have been observed in humans and mice with
disrupted tryptophan hydroxylase genes. Thimm, Richter-Werkle, & Kamp, (2012) found, for
the first time, a significant tyrosine elevation in the cerebrospinal fluid of patients with TT1
under Nitisinone treatment. They also found that serotonin synthesis and release of these patients
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was impaired. Although this research is fairly recent and not yet corroborated with other
research it could help explain the cognitive impairment in TT1 patients.
With an increasing frequency of schooling difficulties, social issues and cognitive deficits
in TT1 patients, it is necessary to further examine the exact pathogenic mechanism of the disease
and the effects of Nitisinone therapy. The disruption of neurotransmitter synthesis, specifically
serotonin, caused by the therapeutic treatment of TT1 can manifest as cognitive dysfunction and
behavioral changes that can be studied using mazes. The Y-maze uses spontaneous alteration to
test learning and memory function. Behavior models have also been utilized as mutant mouse
models of human genetic diseases. Transgenic technology and knockout technology, the ability
to remove a specific gene, make it possible to induce genetic diseases and test hypotheses about
the importance of the gene for the neurotransmitter (Crawley, 1997). Through the use of the Y
maze, this study seeks to answer the research question, Are there differences in the memory of
FAH -/- (diseased) mice prescribed Nitisinone and FAH+/- (disease carrying) mice?
Methods
The sample consisted of: 13 total mice tested – seven males, six females, nine WT (wild
type) (FAH +/-) – six males, three females, four Diseased (FAH-/-) – one male, three females.
The sample of mice were bred from the FAH knockout mice ordered from The Jackson
Laboratory. The original mice received were cryogenically frozen and then thawed and bred.
This mutation was made at Oak Ridge National Laboratories by ENU mutagenesis of BALB/cRl
males which were then bred to (C57BL/10Rl x C3Hf/Rl)F1 females. The offspring of that cross
were bred to a stock bearing Del(Tyr)26DVT, which was generated in (101/Rl x C3H/Rl)F1 then
bred through T Stock. Upon arrival to the biology lab the mice were again genotyped at three-
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four weeks of age for confirmation of their status as either a diseased or a carrier of TT1, as
shown in Figure, 3. All testing was conducted in Dr. MacGregor’s UAH research laboratory.
Spontaneous alternation behavior in a Y-maze was used to test for neurocognitive changes in
memory and learning. Testing was conducted according to previously established procedures.
The mice were kept in the testing room overnight to become familiar to smells and sounds prior
to the maze testing. The Y-maze consisted of three identical gray wooden arms (46cm long,
16cm wide) that were designed at a 120° angle from a center triangle platform, Figure 4. The Ymaze was placed on a table above floor level and white dividers were placed around the maze
area to prevent distraction.

A digital camera captured images and transmitted them to a

computer using EthoVision XT; a video tracking software that tracks and analyzes the behavior,
movement, and activity of each animal tested.
Spontaneous alternation behavior testing in the Y-maze began with a mouse being placed in
the A arm of the maze. Randomization and order of the testing process is shown in Table 1. The
recording of the five minute testing period began as the mouse passed the center of the maze.
The subjects were allowed to freely move through the maze for the entire five minute period and
their arm entries were manually recorded, Table 2.

After each animal, the Y-maze was

thoroughly cleaned with warm water and dried to insure the smell of each animal did not remain
to distract the next animal tested. The spontaneous alternation behavior Y-maze is based off the
tendency for a mouse to explore its environment. The premise being that a normal functioning
rodent, intact memory, will explore each arm of the maze continuously without back tracking.
An alternation is said to have happened when all three of the arms are visited without the back
tracking to a previous arm. These alternations are indicative of memory deficits. For example, if
the mouse travels to arm A, then B and then C followed by movement to arm B, then C, and then
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Each trial is calculated for the percentage of alternation

behavior. The percentage of alternation behavior is figured via the formula:
Percentage of alternation behavior =

actual alternations
maximal alternations

× 100

Results
The highest percentage (86.95%) of spontaneous alternation in movement was achieved
by #32 (wild type)(FAH+/-) mouse, as shown in Figure 6. The lowest spontaneous alternation
(30.77%) was the score for #42 (wild type)(FAH+/-) mouse. Mouse #34 (FAH+/-) jumped out
of the maze at the end; mouse #33(FAH+/-) jumped out of the maze at the end and also spent a
majority of its time on the wall of the maze; and #43(FAH+/-) sat stationary in the center of the
maze often. All three of the previous mentioned mice were wild type, carriers (FAH+/-). Also,
mouse #46 (diseased) (FAH-/-) sat stationary in the center of the maze often during the trial.
The mean percentage for the spontaneous alternations achieved for the wild type mice,
carriers (FAH+/-) was 59.32% and the mean percentage for the diseased mice (FAH -/-) was
60.18% as shown in Figure 7. Furthermore, the mean for the total number of arm entries for the
diseased mice (FAH -/-) was 23 and 23.66 for the carrier mice (FAH +/-), as shown in Figure 5.
Limitations
How this stock of mice was subsequently maintained prior to the Jackson Lab is
uncertain thus the mutant line for mapping is ambiguous. The stock of mice included
contributions from several inbred mice and therefore the exact origins are unknown. Due to the
limited number of diseased mice available at the time of the study the results should not be
generalized. Also, the mice were only 8-10 weeks of age at the time of testing therefore the
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amount of time the mice have been treated with Nitisinone may not have been long enough to
see significant differentiation between the carrier and diseased mice behavior.
Discussion
The diseased mice (FAH -/-) did not show a lower percentage of alternation (i.e. an
altered memory) when tested in the Y-maze but actually scored slightly higher than the carriers.
However, due to the small sample size of only four diseased mice (FAH -/-) the results should
not be interpreted as the diseased mice (FAH -/-) on Nitisinone would perform as well if not
better than the carrier (FAH+/-). Also, because three of the carrier mice (FAH +/-) spent most of
their testing time attempting to escape the maze, most of their activity was not recorded in the
alternation calculation thus lowering the mean score of the carrier mice (FAH+/-). It could be
argued that a more cognitively functioning mouse would most likely attempt to escape the maze.
Furthermore, the amount of time the mice had been treated with Nitisinone should be
taken into consideration. Eight to ten weeks may not be long enough to see cognitive changes.
However, the findings could be used for comparison in future testing using older mice with a
longer duration on the treatment. As the treatment is prolonged and tyrosine levels are elevated
and neurotransmitters are affected the performance in the behavior model could yield a different
result which would provide a significant finding with regards to the effects of both dosage as
well as the duration of time on Nitisinone.
Implications for Future Research
Further research needs to be conducted using a larger sample of at least n=30 to obtain
more accurate results when comparing the carrier to the diseased mouse. More research with a
control group of mice not on the drug as well as wild type mice on the drug would provide a
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more significant finding when comparing Nitisinone as a drug causing neurocognitive decline.
Also, future studies that vary the dosage of Nitisinone within the diseased population of mice
could provide another useful comparison of the negative effects of the drug.
Implications for Nursing Practice
Currently Nitisinone is the only pharmacological treatment for Tyrosinemia Type 1 and
as such its effects on the neurocognitive functioning of patients is of great importance. The
pathophysiological effects of altered amino acids and their direct relationship on
neurotransmitters, particularly serotonin and dopamine, are crucial to the understanding of
patients with Tyrosinemia Type 1 who are being treated with Nitisinone. Neurocognitive and
behavioral changes in patients can influence all aspects of life. Therefore, it is imperative that
health care providers be aware of these possible changes so that the most effective treatment is
pursued and proper education of the patient and family is achieved.
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Table #1: Y-Maze Spontaneous Alternation Test Randomization
December 20, 2013
Identity
34
26
44
33
46
17
43
38
18
32
21
42
20

FAH
WT (+/-)
WT (+/-)
WT (+/-)
WT (+/-)
D (-/-)
WT (+/-)
WT (+/-)
D (-/-)
D (-/-)
WT (+/-)
WT (+/-)
WT (+/-)
D (-/-)

Sex
M
M
M
M
M
M
M
F
F
F
F
F
F

Color
brown
black
brown
brown
light brown
brown
brown
white
white
brown
brown
light brown
white

Cage
(33, 34, 36)
individual
(43, 44, 46)
(33, 34, 36)
(43, 44, 46)
individual
(43, 44, 46)
(38, 42, 45, 47)
(18, 20, 21)
individual
(18, 20, 21)
(38, 42, 45, 47)
(18, 20, 21)

TOTALS:
13 total mice tested – 7 males, 6 females
9 WT(Wild Type Carriers) – 6 males, 3 females
4 Diseased – 1 male, 3 females

Table #2: Alternation Pattern in Y-Maze
Identity
34
26
44
33
46
17
43
38
18
32
21
42
20

FAH
WT (+/+)
WT (+/+)
WT (+/+)
WT (+/+)
D (-/-)
WT (+/+)
WT (+/+)
D (-/-)
D (-/-)
WT (+/+)
WT (+/+)
WT (+/+)
D (-/-)

Sex
M
M
M
M
M
M
M
F
F
F
F
F
F

Alternation Pattern in Y-Maze
CACBABACBABCABABACBA
CBACBACABCBABABABCABCBABACA
BCBACBCABACBCBACBCABCACAB
CBACABACABACBACABACABABCACABACA
CBABCBACACBACCBABCACB
ABCABACACACACBACBCBACB
BACBCBACBACBCABCACACB
CBACBACABCBAACACBABCABABCACBA
CBABCACABCACAB
ACBCABCABABCABCABCABCABCA
CACBABCABACACABCACACABCACABC
CBCACCBACBCBCBC
BCACBACBCACBABCABABCACACBACA
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Figure 1: Catabolic Pathway of Tyrosine

*Nitisinone is labeled NTBC
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Figure 2: Longitudinal IQ levels of patients on Nitisinone
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Figure 3: Genotyping

Figure 4: Y-Maze
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Figure 5: Averages for total arm entries in Y-Maze

Figure 6: Percentage of Alternation Behavior
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Figure 7: Diseased vs Carrier Comparison Graph
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